SCHEMBL3897328

SCHEMBL3897328

NC(=S)Nc1cc(S(=O)(=O)O)cc2cc(S(=O)(=O)O)ccc12.[NaH]

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CASP6 P55212 5/20 0.48
▸ PRMT1 Q99873 2/20 0.47
▸ NSD2 O96028 3/20 0.47
▸ DUSP3 P51452 2/20 0.47
▸ PTPN5 P54829 2/20 0.47
▸ PTPN11 Q06124 2/20 0.47
▸ ALDH1A1 P00352 4/20 0.45
▸ CYP2C9 P11712 2/20 0.45
▸ CYP2C19 P33261 2/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ NT5E P21589 3/20 0.44
▸ CTDSP1 Q9GZU7 1/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ ALOX12 P18054 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4022032 0.98 CASP6 (0.49) CASP6PRMT1NSD2DUSP3PTPN5
SCHEMBL3897862 0.98 CASP6 (0.49) CASP6PRMT1NSD2DUSP3PTPN5
SCHEMBL3895091 0.87 NT5E (0.55) CASP6PRMT1NSD2DUSP3PTPN5
SCHEMBL3895105 0.85 NT5E (0.56) CASP6PRMT1NSD2DUSP3PTPN5
SCHEMBL16328859 0.84 CASP6 (0.56) CASP6PRMT1NSD2DUSP3PTPN5
SCHEMBL3897326 0.82 SIRT1 (0.48) CASP6PRMT1ALDH1A1CYP2C9CYP2C19
SCHEMBL10900256 0.81 PRMT1 (0.63) CASP6PRMT1NSD2DUSP3PTPN5
SCHEMBL20299286 0.79 CASP6 (0.74) CASP6PRMT1NSD2DUSP3PTPN5
SCHEMBL27567387 0.78 TIMP3 (0.40) CASP6ALDH1A1CYP2C9CYP2C19HSD17B10
SCHEMBL3910184 0.78 CASP6 (0.47) CASP6PRMT1NSD2DUSP3PTPN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572459-B2 Prevention infections in humans, animals STARPHARMA PTY LTD. (AU) 2009-08-11 — — US disclosed
EP-1113806-B1 ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS STARPHARMA PTY LTD (AU) 2007-09-05 — — EP disclosed
EP-0765357-B9 ANTIVIRAL DENDRIMERS STARPHARMA PTY LTD (AU) 2006-08-16 — — EP disclosed
EP-0927217-B1 ANGIOGENIC INHIBITORY COMPOUNDS STARPHARMA PTY LTD (AU) 2006-05-03 — — EP disclosed
EP-0765357-B8 ANTIVIRAL DENDRIMERS STARPHARMA PTY LTD (AU) 2006-03-08 — — EP disclosed
EP-0765357-B1 ANTIVIRAL DENDRIMERS BIOMOLECULAR RES INST LTD (AU) 2005-12-14 — — EP disclosed
US-6740635-B2 AIDS THERAPY, RESPIRATORY SYNCYTIAL VIRUS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 2004-05-25 — — US disclosed
EP-1113805-A4 INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS STARPHARMA LTD (AU) 2004-05-19 — — EP disclosed
US-20030129158-A1 Anionic or cationic dendrimer antimicrobial or antiparasitic compositions STARPHARMA LIMITED 2003-07-10 — — US disclosed
EP-1113806-A4 ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS STARPHARMA LTD (AU) 2003-06-25 — — EP disclosed
US-6190650-B1 FOR PROPHYLAXIS AND THERAPY OF VIRAL DISEASES IN HUMANS AND ANIMALS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 2001-02-20 — — US disclosed
WO-2000015240-A1 ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS STARPHARMA LIMITED (AU) 2000-03-23 — — WO disclosed
WO-2000015239-A1 INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS STARPHARMA LIMITED (AU) 2000-03-23 — — WO disclosed
EP-0928306-A1 ANTIVIRAL LINEAR POLYMERS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1999-07-14 — — EP disclosed
EP-0927217-A1 ANGIOGENIC INHIBITORY COMPOUNDS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1999-07-07 — — EP disclosed
WO-1998003573-A1 ANGIOGENIC INHIBITORY COMPOUNDS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1998-01-29 — — WO disclosed
WO-1998003572-A1 ANTIVIRAL LINEAR POLYMERS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1998-01-29 — — WO disclosed
EP-0765357-A4 ANTIVIRAL DENDRIMERS BIOMOLECULAR RES INST LTD (AU) 1997-07-30 — — EP disclosed
EP-0765357-A1 ANTIVIRAL DENDRIMERS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1997-04-02 — — EP disclosed
WO-1995034595-A1 ANTIVIRAL DENDRIMERS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1995-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030129158-A1 Anionic or cationic dendrimer antimicrobial or antiparasitic compositions FUT6, B3GNT2, SIGLEC7 CASP6 1129/4885PRMT1 1218/4885NSD2 4598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback